Bionano Genomics (Bionano Genomics) Debt-to-Revenue : 1.08 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Bionano Genomics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Bionano Genomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $31.54 Mil. Bionano Genomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $6.33 Mil. Bionano Genomics's annualized Revenue for the quarter that ended in Mar. 2024 was $35.08 Mil. Bionano Genomics's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 1.08.

Bionano Genomics Debt-to-Revenue Historical Data

The historical data trend for Bionano Genomics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionano Genomics Debt-to-Revenue Chart

Bionano Genomics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

1.98

1.92

0.60

0.42

2.20

Bionano Genomics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															0.38	0.31	0.27	1.85	1.08

Competitive Comparison of Bionano Genomics's Debt-to-Revenue

For the Medical Instruments & Supplies subindustry, Bionano Genomics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bionano Genomics's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bionano Genomics's Debt-to-Revenue falls into.

Bionano Genomics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Bionano Genomics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(72.238	+	7.175)	/	36.116
	=	2.20

Bionano Genomics's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(31.539	+	6.33)	/	35.076
	=	1.08

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Bionano Genomics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionano Genomics (Bionano Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (NAS:BNGOW) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

BNGO:USA BNGO:Mexico

Address

9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://bionano.com

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas.